The on-body device delivers Udenyca, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
The study reveals the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.
The initiative aims to elevate the professional capabilities of pharmacy technicians and foster leadership qualities essential for advancing in their careers.